Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Achieve Life Sciences, retaining the price target of $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Achieve Life Sciences’ promising smoking cessation treatment, cytisinicline. The FDA has accepted the New Drug Application (NDA) for cytisinicline, with a Prescription Drug User Fee Act (PDUFA) date set for June 2026, marking a significant milestone in the drug’s approval process. The treatment has demonstrated substantial efficacy in its Phase 3 trials, ORCA-2 and ORCA-3, where it significantly increased smoking abstinence rates compared to placebo, with participants showing a 6 to 8 times higher likelihood of quitting smoking.
Furthermore, if approved, cytisinicline would be the first new FDA-approved smoking cessation treatment in two decades, addressing a critical unmet need for millions of smokers. The drug’s favorable safety profile, with no serious adverse events reported, and its potential for a personalized treatment approach, further strengthen its market potential. These factors collectively underpin McCarthy’s optimistic outlook and Buy rating for Achieve Life Sciences’ stock.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $11.00 price target.
ACHV’s price has also changed slightly for the past six months – from $2.850 to $2.860, which is a 0.35% increase.